Modulation of Expression of Endothelial Nitric Oxide Synthase by Nordihydroguaiaretic Acid, a Phenolic Antioxidant in Cultured Endothelial Cells

SANTHINI RAMASAMY, GRANT R. DRUMMOND, JOON AHN, MICHAL STOREK, JAN POHL, SAMPATH PARTHASARATHY, and DAVID G. HARRISON

Division of Cardiology (S.R., G.R.D., J.A., D.G.H.), Department of Gynecology and Obstetrics (S.P.), and Microchemical Facility (M.S., J.P.), Emory University, Atlanta, Georgia

Received March 30, 1999; accepted April 5, 1999

ABSTRACT

Retrospective epidemiological studies have suggested that antioxidant therapy may decrease cardiovascular morbidity and mortality rates, although the mechanisms for this effect remain unclear. In the present study, we demonstrate that selective antioxidants can enhance expression of endothelial nitric oxide synthase (eNOS). We found that the antioxidants nordihydroguaiaretic acid (NDGA), catechol, glutaryl probucol, and N-acetylcysteine increased eNOS expression in cultured bovine aortic endothelial cells (BAECs). NDGA seemed to be the most potent of the phenolic antioxidants, producing a 3-fold increase in eNOS mRNA. This effect of NDGA was enhanced by nonphenolic antioxidants such as N-acetylcysteine and ascorbic acid. Nuclear run-on studies indicated that NDGA increased eNOS transcription. A similar increase in eNOS protein content was observed with Western blot analysis after treating BAECs with NDGA. Exposure of BAECs to NDGA enhanced NO production, as measured by electron paramagnetic resonance spin trapping and eNOS activity, as measured by [14C]arginine-to-[14C]citrulline assay. Methylation of the phenolic hydroxyl groups completely inhibited the NDGA effect on eNOS mRNA levels. This effect of NDGA was not due to inhibition of lipoxigenase because cis-5,8,11,14-eicosatetraynoic acid did not alter eNOS expression. We conclude that antioxidants may not only increase the bioactivity of nitric oxide but also enhance expression of the eNOS enzyme. Such an effect may prove useful in conditions such as hypertension and atherosclerosis, in which nitric oxide production and/or biological activity is impaired.

Endothelium-derived nitric oxide (NO) plays an important role in the modulation of vascular tone and regulation of blood pressure. Moreover, NO inhibits platelet aggregation, smooth muscle proliferation, and leukocyte adhesion to the endothelium (Moncada and Higgs, 1993; Forstermann et al., 1994). In several pathological conditions, such as hypercholesterolemia, atherosclerosis, diabetes mellitus, and hypertension, endothelium-dependent relaxation is impaired. Reactive oxygen species appear to play an important role in the progression of most of these disease states (Freiman et al., 1986; Giugliano et al., 1995; Keaney and Vita, 1995; Rajagopal et al., 1996). More specifically, it has been observed that there is increased production of vascular superoxide, which on reaction with NO results in loss of biological activity of NO.

In patients with non-insulin-dependent diabetes mellitus or hypertension or who are cigarette smokers, acute infusions of ascorbic acid have been shown to improve vasorelaxation (Heitzer et al., 1996; Ting et al., 1996, 1997; Solzbach et al., 1997). In cholesterol-fed rabbits, the impairment in endothelium-dependent relaxation is, in part, reversed by treatment with antioxidants such as vitamin E (Keaney et al., 1993, 1994). Even oral administration of antioxidants has been shown to improve endothelium-dependent vasodilation (Simon et al., 1993; Levine et al., 1996). Although the mechanism by which antioxidant treatment improves vasorelaxation is not clear, it is generally assumed that antioxidants scavenge superoxide and thus increase the availability of functional NO. Kinetic constants, however, suggest that the rate of reactions between common antioxidants and superoxi-
ide is much slower than the rate of the reaction between superoxide and NO (Forman and Fridovich, 1973; Afenas’ev, 1991; Huie and Padmaja, 1993). This raises the possibility that antioxidants may have other effects on the endothelial arginine/NO pathway beyond scavenging superoxide and prolonging the half-life of NO.

Recent evidence suggests that antioxidants can modulate gene expression. For example, antioxidant treatment has been shown to induce expression of chemoprotective enzymes like glutathione S-transferase (Rushmore et al., 1991) and NAD(P)H:quinone reductase (Favreau and Pickett, 1993) and thus prevent cells from malignant transformation. In addition, phenolic antioxidants have been shown to inhibit expression of genes involved in inflammatory processes such as vascular cell adhesion molecule and intercellular adhesion molecule (Cominacini et al., 1996). Of interest, the promoter of human endothelial nitric oxide synthase (eNOS) gene contains simian virus 40 promoter factor 1 (Sp-1), activator protein 1 (AP-1), and antioxidant response elements, all of which are regulated by cellular redox state (Sen and Packer, 1996; Palmer and Paulson, 1997). Based on these considerations and the previous findings in experimental animals, we performed the present study to test the hypothesis that antioxidants might modulate eNOS gene expression.

### Materials and Methods

**Cell Culture and Experimental Media Preparation.** Bovine aortic endothelial cells (BAECs) were cultured in Medium 199 (M199; GIBCO, Grand Island, NY) containing 10% FCS (HyClone Laboratories, Logan, UT) as described previously (Mugge et al., 1991). Postconfluent cells between passages 5 and 10 were used for the experiments. Human aortic endothelial cells (HAECs) were obtained from Clonetics (Walkersville, MD) and cultured in endothelial cell growth media (EGM; Clonetics) containing 2% FCS.

Postconfluent endothelial cells were exposed to control (M199 plus 5% FCS in the case of BAECs or EGM plus 2% FCS in the case of HAECs) or media supplemented with one of several phenolic antioxidants, including nordihydroguaiaretic acid (NDGA), vitamin E, catechol, caffeic acid, butylated hydroxy toluene (BHT), and glutaryl probucol, a water-soluble form of probucol (Table 1). In other experiments, water-soluble antioxidants such as ascorbic acid, cysteine, or N-acetylcysteine (NAC) were used. Concentrated stocks of phenolic antioxidants were made in ethanol, and the appropriate aliquots were added to M199 plus 5% FCS in the case of BAECs or EGM in the case of HAECs to prepare antioxidant-enriched media. The concentration of ethanol in the antioxidant-enriched media was never higher than 0.1%. In the case of water-soluble antioxidants, concentrated stocks were made in distilled water and sterile filtered, and appropriate aliquots were added to M199 plus 5% FCS or EGM.

### TABLE 1

<table>
<thead>
<tr>
<th>Name and Structure of Antioxidant</th>
<th>µM</th>
<th>eNOS/28s fold increase above control</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDGA</td>
<td>16</td>
<td>1.8 ± 0.1</td>
</tr>
<tr>
<td></td>
<td>32</td>
<td>2.9 ± 0.2</td>
</tr>
<tr>
<td>Catechol</td>
<td>50</td>
<td>1.4 ± 0.04</td>
</tr>
<tr>
<td></td>
<td>100</td>
<td>3.2 ± 0.2</td>
</tr>
<tr>
<td>Caffeic acid</td>
<td>100</td>
<td>0.8 ± 0.04</td>
</tr>
<tr>
<td></td>
<td>200</td>
<td>0.9 ± 0.03</td>
</tr>
<tr>
<td>Vitamin E</td>
<td>25</td>
<td>1.0 ± 0.02</td>
</tr>
<tr>
<td></td>
<td>50</td>
<td>1.0 ± 0.1</td>
</tr>
<tr>
<td>BHT</td>
<td>50</td>
<td>0.8 ± 0.03</td>
</tr>
<tr>
<td></td>
<td>100</td>
<td>Toxic</td>
</tr>
<tr>
<td>Glutaryl probucol</td>
<td>10</td>
<td>1.7 ± 0.1</td>
</tr>
<tr>
<td></td>
<td>25</td>
<td>Toxic</td>
</tr>
</tbody>
</table>
Synthesis of Methylated NDGA. NDGA (100 mg; 0.33 mmol) was dissolved in 0.21 ml (3.3 mmol) of isomethane and 5 ml of dry acetone. Potassium carbonate (0.92 g) was then added to the mixture, and the mixture was refluxed for approximately 10 h. Complete methylation was monitored by thin-layer chromatography on silica plates using ethyl acetate/petrol ether (19:1, v/v) as the mobile phase, and the detection was done using iodine vapors. The reaction mixture was evaporated on a rotary evaporator and extracted with ether. After evaporation of ether, the residue was dissolved in 2.0 ml of methanol/water (17:3, v/v).

Methylated NDGA (Me₄NDGA) was purified using reversed phase HPLC on a C18 Microsorb-MV silica column (5 x 250 mm, dp = 5 µm, 100-A pore size; Rainin Instruments) at a flow rate of 0.5 ml/min at room temperature. The column was developed using methanol/water (4:1, v/v) under isocratic conditions, followed by UV detection at 280 nm. The retention time of completely methylated NDGA was 29 min.

The mass of Me₄NDGA was confirmed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, performed using the Bruker ProteinTOF instrument. The sample was prepared according to Storek and Pohl (1997). Briefly, 1.5 µl (1 nmol) of the sample was mixed with 5 µl of the saturated solution of indole-2-carboxylic acid. An aliquot (0.5 µl) of this mixture was deposited on the target, air dried, and analyzed. Spectra were obtained by averaging 50 single-laser-shot spectra. Parameters were set for laser wavelength of 337 nm, ion acceleration voltage of 17.5 kV, and reflector voltage of 20 kV.

Northern Blotting. Total RNA was extracted using TRI reagent (Molecular Research Center, Inc., Cincinnati, OH). RNA (20 µg) was loaded on a 1.0% agarose/0.5% formaldehyde gel, electrophoresed, and transferred to a nitrocellulose membrane overnight. A full-length reflector voltage of 20 kV.

Northern blot analysis showing the effect of increasing concentrations of NDGA on eNOS mRNA in BAECs. Postconfluent BAECs were exposed to 0 to 32 µM NDGA in M199 plus 5% FBS for 24 h. A, representative blot. B, combined densitometric ratio of eNOS/28s RNA. C, percent eNOS/28s rRNA ratio from three separate experiments similar to those shown in C. Data are presented as mean ± SEM.

Fig. 1.

NOS Activity Assay. Postconfluent BAECs were treated with control or antioxidant-containing media for 24 h. Whole-cell homogenates (~250 µg total protein) were then used for NOS activity assay as previously described, and the converted citrulline was separated from labeled L-arginine using a Dowex AG 50WX-8 (Na⁺ form; Bio-Rad, Hercules, CA) (Ramasamy et al., 1998). Radioactivity in the eluate was determined using LS6500 Beckman Liquid Scintillation Counter (Beckman Instruments, Inc., Schumaburg, IL). Protein concentration in the homogenate was determined using Bio-Rad DC reagent.

EPR Spin-trapping for Measurement of NO Production. Confluent BAECs grown in 6-well plates were treated with M199 with 5% FCS containing 0 or 25 µM NDGA for 24 h. The cells were washed in Krebs/HEPES buffer containing 99.01 mM NaCl, 4.69 mM KCl, 1.87 mM CaCl₂, 1.2 mM MgSO₄, 1.03 mM KH₂PO₄, 25.0 mM NaHCO₃, 4.69 mM glucose, pH 7.4, and incubated subsequently with 1.5 ml of the same buffer containing 1.5 mM N-methyl-d-glucamine dithiocarbamate (MGD; Oxis International, Inc., Portland, OR), 0.3 mM ferrous sulfate, and 100 U/ml Cu²⁺/Zn²⁺ superoxide dismutase (SOD) at 37°C. For NO stimulation, cells were incubated in the same buffer mixture containing either 1 µM A23187 or bradykinin. In some experiments, N⁵-nitro-L-arginine methyl ester (L-NAME, 1 mM) was added 30 min before agonist stimulation. After a 30-min incubation, the Krebs/HEPES buffer was removed and immediately frozen in liquid nitrogen. The cell monolayers were dissolved in 0.5% SDS, and total cellular protein content was determined as mentioned above. EPR spectra of the MGD-Fe³⁺-NO complex were recorded using a Bruker EMX EPR spectrometer (Bruker Instruments Inc., Billerica, MA) at microwave frequency of 9.785 GHz, microwave power of 20 mW, modulation frequency of 100 kHz, and modulation amplitude of 2.5 G, at room temperature. A standard curve was obtained by incubating the MGD-Fe³⁺ complex with 0 to 5 µM concentration of the NO donor 2-(N,N-diethylamino)diazonolate-2-oxide, sodium salt (Alexis Biochemicals, San Diego, CA) for 30 min at 37°C, and EPR spectra were obtained under the same conditions as mentioned above for samples. Peak intensity of the EPR spectra was proportional to the amount of

Fig. 2.

EPR Spin-trapping for Measurement of NO Production.
MGD-Fe$^{2+}$-NO complex in the Krebs/HEPES buffer. The total peak intensities of the samples were compared with that obtained for standards allowing quantification of the amount of NO produced by the cells. NO production was normalized to total cellular protein content.

**Western Blotting.** BAECs or HAECs were harvested, and the homogenates were prepared as described in NOS assay. Then, 20 μg of protein was electrophoresed using 7.5% SDS-polyacrylamide gel and transferred to a nitrocellulose membrane. Western analysis was performed using a 1:2000 dilution of a monoclonal antibody against human eNOS (Transduction Laboratories, Lexington, KY) and a secondary goat anti-mouse antibody conjugated to horseradish peroxidase (Amersham Corporation, Arlington Heights, IL) (Ramasamy et al., 1998). Signals of the immunoreactive bands were measured using the ECL detection system (Amersham).

**Nuclear Run-On Assay.** Nuclear run-on assays were performed using a method described by Greenberg (1987) with modifications (Ramasamy et al., 1998). Briefly, BAECs were treated with control or 16 μM NDGA-containing media for 4 h. Cells were harvested and lysed in 0.5% Nonidet P-40, and the nuclei were isolated by centrifugation. In vitro transcription was performed using 5 × 10$^7$ nuclei in a reaction buffer containing a 2 mM concentration each of ATP, GTP, and CTP and 100 μCi of [α-32P]UTP (DuPont-NEN) for 30 min at 30°C. Total RNA was extracted, and the radiolabeled transcripts (total activity, approximately 5 × 10$^6$ cpm) were hybridized to nylon membranes previously slot-blotted with eNOS cDNA, β-actin cDNA, and the full-length pBluescript vector. Bands were subsequently visualized using a PhosphorImager and quantified using ImageQuant software.

**Results**

**NDGA Treatment Causes Dose-Dependent Increase in eNOS mRNA Levels.** Exposure of BAECs to increasing concentrations of NDGA (0–32 μM) for 24 h caused a dose-dependent increase in eNOS mRNA levels as measured by Northern analysis (Fig. 1A). Densitometric readings of the Northern blots indicated that there was an 80 and a 300% increase in the ratios of eNOS to 28S band after 16 and 32 μM NDGA treatments, respectively (Fig. 1B).

Phenolic compounds like NDGA may have both antioxidant and prooxidant effects. In the latter case, the phenolic group is often oxidized to a phenoxy radical, which then can exert prooxidant effects (Santanam and Parthasarathy, 1995). Common mechanisms involve oxidation catalyzed by transition metals and reactions with superoxide. To examine the possibility that NDGA exerted its effect on eNOS mRNA via such a mechanism, cells were concomitantly treated with NDGA plus either SOD or Ca$^{2+}$-EDTA. Neither Ca$^{2+}$-EDTA nor SOD affected eNOS mRNA levels alone, but both augmented the effect of NDGA (Fig. 1, C and D). These data...
suggest that the effect of NDGA on eNOS mRNA levels involves an antioxidant rather than a prooxidant effect.

The structures of several antioxidants, including NDGA, and their effects on eNOS mRNA levels are shown in Table 1. In some instances, the use of higher concentrations of some phenolic antioxidants (BHT and probucol) was limited due to cellular toxicity.

**NDGA-Induced Increase in eNOS mRNA levels Is Transcriptionally Mediated.** NDGA treatment caused an increase in the transcription rate of the eNOS gene but not for β-actin (Fig. 2A). The hybridization of nascent transcripts to eNOS as well as β-actin cDNA in the blots was specific as the hybridization to vector DNA was negligible. Quantitative results from three separate experiments indicated that the ratio of eNOS to β-actin transcription increased 2-fold as a result of NDGA treatment (Fig. 2B).

**Nonphenolic Antioxidants Augment NDGA-Induced Increase in eNOS mRNA Levels.** In BAECs, relatively low concentrations of ascorbic acid (100 μM) or cysteine (200 μM), when given alone, failed to alter eNOS mRNA levels. In contrast, 100 μM ascorbic acid substantially enhanced the effect of 16 μM NDGA on eNOS expression. Quantitative densitometry indicated that combined treatment with NDGA and NAC caused a 2.4- and 1.9-fold increase in eNOS mRNA levels, respectively (Fig. 3B). Similarly, another nonphenolic antioxidant, NAC, when used alone, had no effect on eNOS mRNA levels when added in low concentrations (0.5 mM) for 24 h. A higher concentration of NAC (5 mM) produced a 90% increase in eNOS mRNA, similar to that observed on exposure of cells to 16 μM NDGA. Interestingly, an additive increase in eNOS mRNA levels was found when cells were treated with NDGA and 5.0 mM NAC (Fig. 3, C and D).

**NDGA and NAC Treatments Increase eNOS Protein and Enzyme Activity.** Because NDGA and NAC exerted the most impressive effects on eNOS mRNA levels, studies examining eNOS protein expression and enzyme activity were focused on the effects of these compounds. When used alone, NDGA (16 μM) and NAC (5 mM) increased the eNOS protein content 2- and 2.3-fold, respectively, compared with control BAECs. The combined exposure of NDGA and NAC caused an additive increase (3.5-fold) in eNOS protein content (Fig. 4, A and B). A qualitatively similar effect in eNOS protein expression was observed in HAECs treated with NDGA, NAC, and the combination of the two (Fig. 4, C and D).

In correspondence with the increase in eNOS protein content, both NDGA (16 μM) and NAC (5 mM) elevated eNOS enzyme activity by approximately 2-fold (Fig. 5). Interestingly, the combination of NDGA and NAC, which had a dramatic effect on eNOS protein content, did not increase eNOS enzyme activity beyond that observed when either agent was used alone (Fig. 5).

**Effect of NDGA on Endothelial Cell NO Production.** NDGA (25 μM) elevated NO production as estimated by EPR (Fig. 6) in unstimulated cells as well as cells treated with either A23187 or bradykinin. Representative spectra of MGD-Fe2⁺-NO complexes obtained from control and NDGA-treated BAECs under basal and agonist-stimulated conditions are depicted in Fig. 6A. Analysis of mean data indicated that NDGA approximately doubled NO production under
basal conditions and in response to A23187 and increased responses to bradykinin by 50%. NO production was virtually eliminated by 1 mM L-NAME treatment (Fig. 6B).

**NDGA-Induced Increase in eNOS Expression Is Not Related to Lipoxygenase Inhibition.** Unlike NDGA, the commonly used lipoxygenase inhibitor cis-5,8,11,14-eicosa- tetraynoic acid (ETYA) (50 μM) had no effect on either eNOS enzyme activity (Fig. 7A) or mRNA levels (7B) on 24 h treatment.

**Phenolic Hydroxyl Groups Are Critical for NDGA-Induced Increase in eNOS Expression.** The MALDI-TOF mass spectrum of NDGA after O-methylation confirmed that the molecular weight of the modified molecule, 358.4, amu corresponded to the predicted molecular weight of Me₄NDGA (Fig. 8A). In addition, fast atom bombardment mass spectrometry analysis (not shown) confirmed the presence of four methyl groups. Unlike native NDGA, Me₄NDGA had no effect on eNOS mRNA levels (Fig. 8, B and C). These results indicated that the 4-hydroxyl groups were critical in mediating the effect of NDGA on eNOS mRNA expression.

**Discussion**

The new finding of this study is that antioxidants, including NDGA, NAC, probucol, and catechol, enhance the expression of eNOS in cultured endothelial cells. The most potent of these, the phenolic antioxidant NDGA, increased eNOS expression by as much as 3-fold. This effect of NDGA is at least in part transcriptionally mediated and is augmented by the presence of nonphenolic small antioxidant molecules such as ascorbic acid and NAC. In addition, increased eNOS gene expression by NDGA in endothelial cells is mediated by its phenolic groups, as the methylation of these groups abolished this effect of the compound. Finally, NDGA-mediated increases in eNOS gene expression are likely due to antioxidant rather than prooxidant effects and are independent of lipoxygenase inhibition.

The biological activity of endothelium-derived NO is diminished in a variety of pathophysiological conditions, resulting in impaired endothelium-dependent vasodilation. In hypercholesterolemia, treatment with SOD, dietary antioxidants including beta carotene or vitamin E (Keaney et al., 1993), or the phenolic antioxidant probucol (Keaney et al., 1993) have been shown to improve endothelium-dependent vasodilation. Recently, antioxidant treatment has also been shown to increase endothelium-dependent vasodilation and reduce blood pressure in angiotensin II-induced hypertension (Laursen et al., 1997). In general, it is thought that antioxidants improve endothelium-dependent vasodilation by scavenging superoxide and thus increasing the availability of functional NO (Harrison and Ohara, 1995). The rate constants for the reaction between superoxide and antioxidant vitamins such as vitamin E and ascorbic acid, however, are approximately 10,000 times slower than the rate constant for the reaction between NO and superoxide (Forman and Fridovich, 1973; Afnas’ev, 1991; Huie and Padmaja, 1993). Our current study provides an additional mechanism whereby antioxidants may improve endothelial-dependent vasodilation (i.e., by increasing eNOS expression).

Of interest, the effect of the various phenolic antioxidants on eNOS expression varied substantially (Table 1). The antioxidant properties and the propensity of these compounds to undergo redox cycling are affected by their respective R-groups attached to the aromatic ring. Among the phenolic antioxidants used in this study, NDGA is the most potent. At a concentration of 32 μM, NDGA increased eNOS expression by 3-fold. NDGA has well established antioxidant properties and is known to prevent oxidation of lard stored at room temperature for up to 1 year (Lundberg et al., 1944). NDGA has previously been shown to be more potent than vitamin E, probucol, caffeic acid, or BHT in preventing oxidation of linoleic acid (Sgargali et al., 1993). It is also possible that structural characteristics and hydrophobic properties of the various compounds influence their capacity to interact with redox sensitive transcription factors.

**Fig. 6.** A, EPR spectra of MGD-Fe⁺-NO complex obtained in control and 25 μM NDGA-treated BAECs under basal and agonist-stimulated conditions. EPR spectra were obtained after incubation of the cells in Krebs/HEPES buffer containing 1.5 mM MGD, 0.3 mM ferrous sulfate, and 100 U/ml Cu²+/Zn²⁺ SOD at 37°C for 30 min. The cells were stimulated either with 1 μM A23187 or bradykinin. In some cells, 1 mM L-NAME was added 30 min before agonist stimulation. Spectrometer settings were microwave frequency of 9.785 GHz, microwave power of 20 mW, receiver gain of 1 × 10⁴, modulation frequency of 100 kHz, modulation amplitude of 2.5 G, and scan time of 83.886 s. Images are the averages of five scans subjected to baseline correction. B, quantification of spectra obtained from samples (n = 3) after correction for cellular protein. A standard curve generated by exposure of MGD-Fe⁺ to 2-(N,N-diethylamino)diazonolate-2-oxide (0–5 μM) was used to quantify the actual amount of NO produced by the cells.
Our studies indicate that the phenolic hydroxyl groups of NDGA are necessary for enhancing eNOS expression. When the phenolic hydroxyl groups were methylated, the ability of the modified compound to affect eNOS expression was completely abolished (Fig. 8). Thus, it seems that the presence of the phenolic hydroxyl groups, which are critical for the antioxidant properties of the compound, are also important in enhancing eNOS expression.

Phenolic hydroxyl-containing compounds may exert both antioxidant and prooxidant properties. When a radical abstracts the hydrogen atom of the phenolic group, the phenolic antioxidant is converted to a phenoxy radical. Reducing agents such as ascorbic acid or thiol containing compounds promote reduction of the phenoxy radicals back to the parent compound (Thomas et al., 1995). If the effect of NDGA on eNOS expression were mediated via a prooxidant effect, it would be expected that addition of reducing agents such as ascorbate, cysteine, or NAC would have diminished induction of eNOS by NDGA. This was not found to be the case. Ascorbate and NAC enhanced the effect of NDGA on eNOS expression, whereas cysteine was without effect. Furthermore, the addition of Cu²⁺/Zn²⁺ SOD (to scavenge O₂⁻ in the media) or Ca²⁺-EDTA (to chelate transition metals) enhanced the effect of NDGA. Taken together, these lines of evidence suggest that the effect of NDGA on eNOS expression is mediated via antioxidant rather than prooxidant properties (Fig. 1).

NDGA is also known to be nonselective lipoxygenase inhibitor. It is unlikely, however, that its effect on eNOS expression was mediated via lipoxygenase inhibition (Fig. 7). Neither lipoxygenase protein nor enzyme activity has been detected in endothelial cells. Furthermore, another potent inhibitor of lipoxygenase, ETYA (in concentrations exceeding that necessary to inhibit lipoxygenase), had no effect on eNOS expression or enzyme activity (Reddy et al., 1994).

Nuclear run-on analysis suggested that NDGA enhances the rate of eNOS mRNA transcription (Fig. 2). The promoter of eNOS contains cis-elements that in the case of other genes, are modulated by cellular redox state. In particular, Sp-1 binding is crucial for basal transcription of eNOS. In other genes and tissues, antioxidant treatment has been shown to increase Sp-1 binding, whereas the addition of hydrogen peroxide or diamide or the depletion of glutathione decreases Sp-1 binding. AP-1-like elements are also present in the eNOS promoter. Phenolic antioxidants have been shown to induce expression of c-Fos, and c-Jun, resulting in enhanced AP-1 binding activity in hepatocytes (Choi and Moore, 1993). In contrast, phenolic antioxidants may inhibit AP-1 activity by increasing Fra (Yoshioka et al., 1995). It is also possible that NDGA increases eNOS expression through activation of protein or proteins binding to an antioxidant response element (ARE). Both the human and bovine eNOS promoters contain sequences resembling the ARE in the NAD(P)/H: quinone reductase and the glutathione S-transferase promoters. The presence and significance of ARE-binding proteins in endothelial cells have yet to be examined.

Interestingly, the combination of NDGA with NAC, although increasing eNOS mRNA and protein levels, did not increase eNOS enzyme activity as determined by L-arginine-L-citrulline activity (Figs. 3 and 4 versus Fig. 5). The reason for this discrepancy is unclear, but it may be related...
to either subcellular localization of the enzyme or autoinhibition of enzyme activity as recently described by Griscavage et al. (1995).

In addition to mediating endothelium-dependent vasodilation, endothelium-derived NO has been shown to inhibit platelet aggregation (Alheid et al., 1987), vascular cell adhesion molecule-1 expression (Khan et al., 1996), and smooth muscle growth (Garg and Hassid, 1989), all of which are considered antiatherogenic properties. There is substantial evidence that antioxidants may inhibit the atherosclerotic process, likely via a variety of mechanisms, including prevention of low-density lipoprotein oxidation and inhibition of vascular adhesion molecule expression. Increased expression of NO synthase and production of endothelial NO may be another mechanism whereby antioxidants inhibit the development of atherosclerosis. Modulation of eNOS expression by compounds similar to NDGA may be a useful clinical target for future drug design and clinical studies.

References

Send reprint requests to: Santhini Ramasamy, Ph.D., Division of Cardiology, Emory University, 1639 Pierce Drive, Atlanta, GA 30322. E-mail: sramasa@emory.edu.

Antioxidant and Endothelial NOS Gene Regulation 123

Downloaded from molpharm.aspetjournals.org on July 6, 2017 by ASPET Journals on July 6, 2017 molpharm.aspetjournals.org Downloaded from

Send reprint requests to: Santhini Ramasamy, Ph.D., Division of Cardiology, Emory University, 1639 Pierce Drive, Atlanta, GA 30322. E-mail: sramasa@emory.edu.